ALX vs CSR

The Advanced Deterministic Scorecard reveals a weak financial health profile with a Piotroski F-Score of 4/9, indicating borderline stability, and a concerning lack of Altman Z-Score due to insufficient data. Despite strong profitability metrics like high ROE and gross margin, the company faces significant risks including an extremely high debt/equity ratio of 7.86, negative earnings growth, and a dangerously high payout ratio of 252.10%, which raises sustainability concerns. The stock is trading at $243.04, far above both the Graham Number ($63.22) and intrinsic value estimate ($49.49), suggesting severe overvaluation. While recent price performance has been strong over the past year, weak fundamentals and deteriorating growth trends point to elevated downside risk.

CSR exhibits significant fundamental weakness, anchored by a Piotroski F-Score of 4/9 (Stable) and a severe valuation gap where the current price of $66.49 dwarfs both the Graham Number ($31.38) and the Intrinsic Value ($7.14). The company is facing a liquidity crisis with a Quick Ratio of 0.13 and a Current Ratio of 0.44, indicating an inability to cover short-term obligations. Most alarmingly, the dividend payout ratio of 301.96% is unsustainable, suggesting the dividend is being funded by debt or capital reserves rather than earnings. Despite a 'buy' analyst consensus, the combination of stagnant revenue growth (0.30%) and a negative forward P/E makes the current valuation unjustifiable.